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Abstract
Purpose Serum uric acid (SUA) has antioxidant capaci-
ties and therefore may protect against the development of
cancer. Few epidemiological studies have tested this
hypothesis, and findings were inconsistent.
Methods We studied the association between SUA levels
and mortality due to any type of cancer, and three common
types of cancer among males (lung, colorectal, and prostate
cancer) in the general population-based Vlagtwedde–
Vlaardingen cohort with 38 years of follow-up and 8 sur-
veys (total number of males = 4,350). Of 1,823 males with
data available on SUA, 254 (13.9 %) died due to any
cancer (lung n = 75 (4.1 %), colorectal n = 27 (1.5 %),
and prostate cancer n = 23 (1.3 %), assessed on 31
December 2008). SUA, cholesterol, and triglyceride were
measured in males during the surveys in 1970, 1972, and
1973. We analyzed the association between cancer mor-
tality risk and SUA level both as continuous variable and as
tertiles: lowest \5 mg/dl (reference), middle 5–5.8 mg/dl,
and highest [5.8 mg/dl, using multivariate Cox regression
with adjustment for age, smoking (pack years), and body
mass index.
Results Higher levels of SUA were associated with a
lower risk of mortality from any cancer [HR (95 %
CI) = 0.85 (0.73–0.97)]. SUA levels in the highest tertile
([5.8 mg/dl) were associated with a lower risk of mortality
from any cancer [0.68 (0.48–0.97)]. Additional adjustment
for serum total cholesterol and triglyceride levels did not
change the results.
Conclusions Our study indicates that elevated SUA levels
may protect against cancer mortality.
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Abbreviations
SUA Serum uric acid
HR Hazard ratio
ICD International classification of diseases
BMI Body mass index
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Introduction
Several studies have linked serum uric acid (SUA) levels to
general mortality, cardiovascular disease, or the metabolic
syndrome [1, 2], but only a few epidemiological studies
have addressed the association between SUA and cancer
mortality [3–7]. Moreover, the results of these few studies
are inconsistent. SUA is derived from the oxidation of
xanthine and hypoxanthine (products of purine nucleotides)
by the enzyme xanthine oxidoreductase (XOR) [8, 9]. In
humans, normal SUA level is between 3 and 6.8 mg/dl. A
high SUA level can be derived from purine (purine
nucleotides, adenine, and guanine)-rich diets (e.g., pro-
teins), renal dysfunction in excretion of SUA [9], or as a
result of increased cell apoptosis and necrosis [4]. SUA as
an antioxidant was hypothesized to protect against cancer
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development by its capacity to scavenge oxygen radicals and
inhibit lipid peroxidation [10]. However, results from other
studies do not support this hypothesis, suggesting a pro-
inflammatory role of SUA in specific diseases [4, 9, 11].
The role of SUA as independent factor in the development
of cancer is controversial. Evidence shows there are positive
associations between SUA and established risk factors for
cardiovascular disease, metabolic syndrome, and cancer such
as body mass index (BMI), levels of cholesterol, and triglyc-
eride [4, 5]. Thus, several confounding factors underlying
these comorbidity disorders may have been responsible for a
potential link between SUA levels and cancer.
We aimed to study the association between SUA levels
and cancer mortality and investigate whether this associa-
tion is independent of an individual’s cholesterol and tri-
glyceride levels. The current study examines the
association between SUA and mortality due to any type of
cancer, and due to the three most common types of cancer
in males, i.e., lung, colorectal, and prostate cancer, using
the Vlagtwedde–Vlaardingen cohort [12, 13]. This large
cohort has been followed up for 38 years and offers us the
unique possibility to investigate this association.
Methods
Study population
We studied the association between SUA and mortality from
cancer using the Vlagtwedde–Vlaardingen cohort study.
This study has been described in detail previously [12, 13]. In
brief, the Vlagtwedde–Vlaardingen study was set up as a
general population-based cohort study on the epidemiology
of pulmonary diseases in exclusively Caucasian individuals
of Dutch descent. The study started in 1965, and participants
had medical examinations every 3 years until the last survey
in 1989/1990. In Vlaardingen, only participants who were
included at baseline (1965 or 1969) were approached for
follow-up, whereas in Vlagtwedde new subjects aged
between 20 and 65 years were invited to participate at every
survey. The number of surveys per subject ranges from 1 to 8
(median number of surveys per subject: two). The final
surveys were organized in 1989 in Vlagtwedde and in 1990
in Vlaardingen. SUA, cholesterol, and triglyceride were
measured in males only during the surveys in 1972 (mea-
sured in Vlaardingen), and 1970 and 1973 (measured in
Vlagtwedde). Blood sampling was performed in a fasting
condition. We updated the vital status of all participants in
the Vlagtwedde–Vlaardingen study on 31 December 2008
and evaluated mortality outcomes, i.e., any cancer mortality,
and three common types of cancer mortality, being lung
cancer, colorectal cancer, and prostate cancer, either as pri-
mary or secondary cause of death. Analyses on cause-
specific mortality were performed at Statistics Netherlands
(The Hague, The Netherlands).
Ethics statement
The committee on human subjects in research of the Uni-
versity of Groningen reviewed the study and affirmed the
safety of the protocol and study design and specifically
approved this study. All participants gave their written
informed consent.
Population characteristics
We collected data on age, sex, smoking habits, and place of
residence using the Dutch version of the British Medical
Research Council questionnaire [12].
Serum uric acid, serum total cholesterol,
and triglyceride
Fasting SUA level was determined according to the EDTA-
hydrazine method on an autoanalyzer [14]. Fasting serum
total cholesterol was determined according to the Huang
method [15] on an autoanalyzer. Fasting serum triglycer-
ides concentration was determined according to the Laurell
method [16].
We included only SUA, cholesterol, and triglyceride
level of a male’s first available measurement at survey
1970, 1972, or 1973.
We analyzed SUA levels as a continuous variable and as
tertiles:
1. SUA \5 mg/dl (as reference);
2. SUA 5–5.8 mg/dl
3. SUA [5.8 mg/dl
Cancer mortality
Cancer mortality was classified according to the interna-
tional classification of diseases (ICD) coding system: any
cancer (ICD 7: 140–239, 294; ICD 8: 140–239; ICD 9:
140–239 and 288; ICD 10: C00–C97, D00–D48); lung
cancer (cancer of trachea, bronchus, and lung) (ICD 7: 162,
163; ICD 8: 162, 163; ICD 9: 162, 163, 165; and ICD 10:
C33, C34, C38, and C39); colon and rectal cancer (colo-
rectal cancer) (ICD 7: 153, 154; ICD 8: 153, 154; ICD 9:
153, 154; ICD: 10 C18–C21); and prostate cancer (ICD 7:
177; ICD 8: 185; ICD 9: 185 and ICD: 10: C61).
Statistical analyses
First, descriptive analyses of the male characteristics and
the mortality statistics were performed. Independent
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sample t test, Mann–Whitney U test, and chi-square test were
used to determine significant differences between groups for
continuous and categorical variables, respectively. Triglyc-
eride levels were log-transformed to obtain normality of the
distribution. Secondly, hazard ratios associated with SUA
levels for mortality from any cancer and any of the three
common types of cancer were estimated using multivariate
Cox regression. The Cox regression model was adjusted for
age, BMI, and smoking (pack years), all at first available
survey with data on SUA. Additionally, we adjusted the Cox
regression model for cholesterol and triglyceride levels. In
the Cox regression analyses, censoring took place when the
males were still alive, were lost to follow-up, or died of
causes other than cancer or the specific cancer under study
[17]. Time was defined from the first available survey with
data on SUA, until mortality from any type of cancer or
specific cancer as the end point of interest or until censoring.
p values \0.05 (tested two-sided) were considered to be
statistically significant.
Results
Of all 4,350 males, 2,249 were examined in 1970, 1972, or
1973. In total, 1,823 (81 %) males had data available on
SUA. Subjects who had data available on SUA had a
higher BMI level and a higher number of pack years
compared to subjects who were examined in 1970, 1972, or
1973 but had no data available on SUA. Vital status of
subjects who had data available on SUA was also signifi-
cantly different compared to those with no data on SUA
(results not shown). Of those males with data available on
uric acid, 1,162 (63.7 %) were alive, 254 (13.9 %) died due
to any cancer, 354 (19.4 %) died but not due to cancer, and
29 (1.6 %) died due to external causes (e.g., an accident,
suicide, or homicide), in 5 (0.3 %) males the cause of death
could not be determined and 19 (1.0 %) were lost to fol-
low-up (Table 1). Of those males who died due to cancer,
75 (29.5 %) died due to lung cancer, 27 (10.6 %) died due
to colorectal cancer, and 23 (9.1 %) died due to prostate
cancer (Table 1). The mean age at the first SUA survey of
males who died due to cancer was 42.3 (SD = 8.9). Males
who died due to cancer had a significantly lower level of
SUA compared to males who were alive.
Serum uric acid
Higher levels of SUA were significantly associated with a
lower risk of mortality from any cancer [HR (95 % CI):
0.85 (0.73–0.97)] (Table 2-model 1). SUA levels higher
than 5.8 mg/dl were significantly associated with a lower
risk of mortality from any cancer [0.68 (0.48–0.97)]
(Table 2-model 1; Fig. 1). Additional adjustment for total
blood cholesterol and triglyceride level did not change the
results (Table 2-model 2).
Discussion
This is the first study showing that SUA levels are asso-
ciated with a lower risk of mortality from any type of
cancer in males from a general population cohort followed
up for 38 years. This association remained after adjustment
for serum total cholesterol and triglyceride levels.















Age (years), mean (SD) 31.9 (8.5) 42.3 (8.9)b 44.2 (8.0) 38.3 (11.3) 30.7 (9.7)
Smoking (pack years), median (range) 6.0 (0.0–82.2) 16.4 (0.0–80.4)b 18.4 (0.0–68.2) 15.0 (0.0–78.7) 5.5 (0.0–31.5)
BMI kg/m2, mean (SD) 25.0 (3.0) 25.5 (3.0)b 25.9 (3.0)c 25.9 (3.5) 25.2 (2.5)
SUA (mg/dl), mean (SD) 5.5 (0.9) 5.2 (1.0)b 5.4 (1.0) 5.5 (1.2) 5.8 (1.1)
Tertiles of SUA (mg/dl), n %
\5 369 (31.7) 108 (42.5)b 135 (37.8) 12 (40.0) 4 (21.1)
5–5.8 423 (36.3) 88 (34.6) 120 (33.6) 8 (26.7) 6 (31.6)
[5.8 372 (32.0) 58 (22.8) 103 (28.8) 10 (33.3) 9 (47.4)
Serum total cholesterol (mg/dl), mean (SD) 235.8 (45.6) 253.9 (42.5)b 261.3 (48.3)c 251.0 (47.1) 244.2 (44.0)
Triglyceride (mg/dl) (Log 10), mean (SD) 2.0 (0.2) 2.0 (0.2) 2.1 (0.2)c 2.0 (0.3) 2.0 (0.2)
a Males: n = 1,823; in 5 (0.3 %) males, the cause of death could not be determined
b Significantly different from males who were alive (p value calculated by chi-square or t test \0.05)
c Significantly different from males who died due to any type of cancer (p value calculated by chi-square or t test \0.05)
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Ames et al. [10] for the first time hypothesized that SUA
provides a primary defense against human cancer by its
role as a scavenger of singlet oxygen, hydroxyl radical (a
product of singlet oxygen conversion), and suppresses the
lipid peroxidation in erythrocytes. Further support for the
antioxidant role of SUA has been identified in many dif-
ferent organ systems [18].
While there is some support for this hypothesis among
epidemiological studies, this idea has been strongly
supported by molecular investigations, suggesting that an
indirect pharmacological reduction in SUA levels, by
inhibiting the XOR receptor, provokes tumorigenesis [19,
20]. Another example that supports the antioxidant
capacity of SUA is a recent study on the link between a
broad range of oxidative stress parameters and colon can-
cer survival [21]. Authors reported that among plasma
antioxidants only higher uric acid levels were associated
with longer survival among colon cancer patients [21].
They suggested that SUA acts as the main antioxidant by
scavenging the free radicals and stabilizing ascorbic acid in
human serum [21, 22]. However, this study was performed
among cancer patients. So far, there is no evidence to show
whether SUA levels in healthy males provide a primary
defense against cancer.
The majority of studies on the potential antioxidant
properties of SUA are based on mortality in general, so
reliable information about subgroup and different cancer
types is scarce. Moreover, only few studies have controlled
for the blood lipid profile of the subjects [4, 6]. One of these
studies with control for lipid profile found no association
between SUA levels and cancer mortality after adjustment
for age, current smoking, diabetes, hypertension, and
hypercholesterolemia [4]. However, this study was restricted
to a specific population; the SUA measurements were
obtained only among subjects who had an abnormal value of
total cholesterol or urinary protein levels [4].
Others have reported that high levels of SUA were
associated with a higher risk of mortality from cancer
among males after adjustment for established risk factors
such as cholesterol [6, 7]. The finding of an increased risk
Table 2 Hazard ratio (with 95 % confidence interval) of serum uric
acid (SUA) for mortality from any cancer, lung cancer, colorectal
cancer, and prostate cancer among 1,823 males (n = 1,723 without
missing values on confounders). Cox regression models with
adjustment for age, BMI, smoking (pack year) at the first survey
with data available on SUA. Additional adjustments for lipid profile
(cholesterol and triglyceride) in model 2 (n = 1,713 without missing
values on confounders)
Any cancer Lung cancer Colorectal cancer Prostate cancer
N events HR 95 % CI N events HR 95 % CI N events HR 95 % CI N events HR 95 % CI
Model 1: Without adjustment for lipid profile
SUA mg/dl 235 0.85 0.73–0.97 75 0.77 0.60–1.00 24 1.02 0.65–1.58 18 0.62 0.37–1.04
SUA tertiles, mg/dl
\5.0 103 1 34 1 10 1 9 1
5.0–5.8 82 0.93 0.70–1.25 28 0.97 0.59–1.60 9 1.27 0.51–3.19 8 1.19 0.46–3.17
[5.8 50 0.68 0.48–0.97 13 0.53 0.27–1.01 5 0.84 0.28–2.50 1 0.14 0.02–1.12
Model 2: With adjustment for lipid profile
SUA mg/dl 234 0.86 0.75–1.00 74 0.84 0.64–1.08 24 1.04 0.66–1.65 18 0.60 0.35–1.01
SUA tertiles, mg/dl
\5.0 102 1 33 1 10 1 9 1
5.0–5.8 82 0.95 0.70–1.27 28 1.01 0.60–1.69 9 1.31 0.51–3.33 8 1.13 0.43–3.00
[5.8 50 0.70 0.49–0.99 13 0.55 0.28–1.08 5 0.88 0.29–2.69 1 0.12 0.01–1.02
Statistically significant results are shown in bold
Fig. 1 Cox proportional hazard survival curves according to different
categories of SUA at first available survey on any types of cancer
mortality risk for males
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of cancer can be explained by the fact that SUA levels may
have been altered by preexisting disease (cancer) at the
time of measurement since hyperuricemia can be an indi-
cator of the tumor lysis syndrome. The tumor lysis syn-
drome is a result of the rapid intracellular release of dying
cancer cell’s contents, which may lead to hyperuricemia as
well as other metabolic disorders [23]. Thus, an increased
nucleic acid turnover in the rapid proliferation of neoplastic
cells may lead to an increased level of SUA [7]. A sensi-
tivity analysis, excluding those subjects who died within
5 years of the baseline SUA measurement (n = 26 of
which eight died of cancer), resulted in similar associations
between SUA level and cancer mortality, indicating that
the effect of possible inclusion of cancer patients at base-
line is minimal in our study (results not shown).
It is also possible that the increased risk to develop
cancer may not be due to SUA, but that high SUA levels
rather reflect an unhealthy lifestyle with an increased
cancer risk [6].
The association between SUA levels and cancer is known
to vary by cancer type. One study reported that SUA levels
were positively associated only with cancer mortality of
digestive and respiratory systems, and intra-thoracic organs
[6]. However, we did not find this association.
Based on the concentrations, some studies reported a
U-shaped or J-shaped association between SUA and cancer
mortality [3, 24, 25]. Kua et al. [3] reported a U-shaped
association between SUA and all-cause and cancer mor-
tality, with a negative association between SUA levels and
mortality when the SUA levels range from 0.3 to
0.4 mmol/l, which is equivalent to 5–6.9 mg/dl The vast
majority of our population (59.1 %) had SUA levels
between 5 and 6.9 mg/dl; thus, our negative association is
in accordance with the results of Kua et al. [3]. The mean
SUA level in our population is lower than reported in other
studies (mean = 5.4 mg/dl). This can be explained by the
fact that in our study SUA levels were measured between
1970 and 1973 while other studies were more recent. In
recent decades, SUA levels in the general population tend
to increase, which is due to various changes in lifestyle
factors including increased purine-rich diets and alcohol
consumption [26]. Thus, having a lower range of SUA
levels in our population compared to other general popu-
lations seems to be reasonable.
However, data from epidemiological studies suggest that
the beneficial or detrimental effects of SUA are not only
dependent on its concentration, but also influenced by
several metabolic environmental and genetic factors [27],
which makes comparisons across studies difficult.
Although information on major risk factors such as age,
BMI, and cholesterol and triglyceride was collected, our
study did not assess some other factors that may affect
SUA level such as impaired renal function, hypertension,
diabetes, and diet. Another limitation is that the SUA
measurements were available only in males and thus
results cannot be generalized to females. Finally, the
impact of changes in SUA levels during follow-up on risk
of cancer mortality could not be investigated in our study.
Therefore, the risk of cancer mortality in relation to SUA
could be underestimated by considering only single
measurements (i.e., at baseline). Thus, further studies are
needed to clarify the association between SUA and risk of
cancer mortality.
The major strength of our current study is the longitu-
dinal design. We were able to follow our participants for
38 years, which provided a unique wide time window for
evaluating the risk of SUA levels on cancer mortality.
Other strengths of our study are the large number of males
included, and the high follow-up rate, since 98.5 % of the
included males could be traced back [28].
In conclusion, this study shows that a higher SUA level
is associated with a lower risk of cancer mortality.
Acknowledgments This work was supported by the Netherlands
Asthma Foundation (Grant Numbers 187 and 32.96.69), and Stichting
Astma Bestrijding (Grant Number 2005/020), and guide.
Conflict of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Soltani Z, Rasheed K, Kapusta DR et al (2013) Potential role of
uric acid in metabolic syndrome, hypertension, kidney Injury, and
cardiovascular diseases: is it time for reappraisal? Curr Hypertens
Rep 15:175–181
2. Zhao G, Huang L, Song M et al (2013) Baseline serum uric acid
level as a predictor of cardiovascular disease related mortality
and all-cause mortality: a meta-analysis of prospective studies.
Atherosclerosis 231:61–68
3. Kuo CF, See LC, Yu KH et al (2013) Significance of serum uric
acid levels on the risk of all-cause and cardiovascular mortality.
Rheumatology (Oxford) 52:127–134
4. Jee SH, Lee SY, Kim MT (2004) Serum uric acid and risk of
death from cancer, cardiovascular disease or all causes in men.
Eur J Cardiovasc Prev Rehabil 11:185–191
5. Fini MA, Elias A, Johnson RJ et al (2012) Contribution of uric acid
to cancer risk, recurrence, and mortality. Clin Transl Med 1:1–16
6. Strasak AM, Rapp K, Hilbe W et al (2007) Serum uric acid and
risk of cancer mortality in a large prospective male cohort.
Cancer Causes Control 18:1021–1029
7. Petersson B, Trell E (1983) Raised serum urate concentration as
risk factor for premature mortality in middle aged men: relation
to death from cancer. Br Med J (Clin Res Ed) 287:7–9
8. Hille R (2005) Molybdenum-containing hydroxylases. Arch
Biochem Biophys 433:107–116
Cancer Causes Control (2014) 25:1075–1080 1079
123
9. Wu L, Wu JT (2008) Serum uric acid is a marker of inflammation
and a marker predicting the risk of developing CVD, stroke, renal
failure and cancer. J Biomed Lab Sci 20:1–2
10. Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides
an antioxidant defense in humans against oxidant- and radical-
caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA
78:6858–6862
11. Kanbay M, Segal M, Afsar B et al (2013) The role of uric acid in
the pathogenesis of human cardiovascular disease. Heart
99:759–766
12. Hospers JJ, Schouten JP, Weiss ST et al (2000) Eosinophilia is
associated with increased all-cause mortality after a follow-up of
30 years in a general population sample. Epidemiology 11:261–268
13. van der Lende R, Kok TJ, Reig RP et al (1981) Decreases in VC
and FEV1 with time: indicators for effects of smoking and air
pollution. Bull Eur Physiopathol Respir 17:775–792
14. Patel CP (1968) Semimicro method for determination of serum
uric acid using EDTA-hydrazine. Clin Chem 14:764–775
15. Huang YC, Kao JT, Tsai KS (1997) Evaluation of two homo-
geneous methods for measuring high-density lipoprotein choles-
terol. Clin Chem 43:1048–1055
16. Laurell S (1966) A method for routine determination of plasma
triglycerides. Scand J Clin Lab Invest 18:668–672
17. Prentice RL, Kalbfleisch JD, Peterson AV et al (1978) The ana-
lysis of failure times in the presence of competing risks. Biom J
34:541–554
18. Becker BF (1993) Towards the physiological function of uric
acid. Free Radic Biol Med 14:615–631
19. Linder N, Martelin E, Lundin M et al (2009) Xanthine oxidore-
ductase—clinical significance in colorectal cancer and in vitro
expression of the protein in human colon cancer cells. Eur J
Cancer 45:648–655
20. Kim AW, Batus M, Myint R et al (2011) Prognostic value of
xanthine oxidoreductase expression in patients with non-small
cell lung cancer. Lung Cancer 71:186–190
21. Dziaman T, Banaszkiewicz Z, Roszkowski K et al (2013) 8-Oxo-
7,8-dihydroguanine and uric acid as efficient predictors of sur-
vival in colon cancer patients. Int J Cancer 10:1002
22. Schlotte V, Sevanian A, Hochstein P et al (1998) Effect of uric
acid and chemical analogues on oxidation of human low density
lipoprotein in vitro. Free Radic Biol Med 25:839–847
23. Mika D, Ahmad S, Guruvayoorappan C (2012) Tumour lysis
syndrome: implications for cancer therapy. Asian Pac J Cancer
Prev 13:3555–3560
24. Edlinger M, Nagel G, Hilbe W et al (2011) Associations of serum
uric acid and gamma-glutamyltransferase with cancer in the
Vorarlberg health monitoring and promotion programme
(VHM&PP)—a short review. Mag Eur Med Oncol 4:50–54
25. Strasak AM, Lang S, Kneib T et al (2009) VHM&PP study group.
Use of penalized splines in extended Cox-type additive hazard
regression to flexibly estimate the effect of time-varying serum
uric acid on risk of cancer incidence: a prospective, population-
based study in 78,850 men. Ann Epidemiol 19:15–24
26. Rho YH, Zhu Y, Choi HK (2011) The epidemiology of uric acid
and fructose. Semin Nephrol 31:410–419
27. Alvarez-Lario B, Macarron-Vicente J (2011) Is there anything
good in uric acid? QJM 104:1015–1024
28. Figarska SM, Boezen HM, Vonk JM (2012) Dyspnea severity,
changes in dyspnea status and mortality in the general population:
the Vlagtwedde/Vlaardingen study. Eur J Epidemiol 27:867–876
1080 Cancer Causes Control (2014) 25:1075–1080
123
